ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0291

Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics

Shun Nomura, Yasuhiro Shimojima, Takanori Ichikawa, Daigo Miyazaki, Dai Kishida and Yoshiki Sekijima, Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan

Meeting: ACR Convergence 2023

Keywords: ANCA associated vasculitis, Myopathies, Myositis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0283–0307) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Muscular involvement develops as the initial manifestation of small-sized vessel vasculitis (SV) and medium-sized vessel vasculitis (MV).The musculoskeletal lesion has been found as a crucial biopsy site including the histology of SV and MV unless another suitable organ for a biopsy can be found. However, immunopathological features, including the degree of myofiber damage, in the histology of vasculitic myopathy (VM) have been still unknown, while pathological assessment is an ideal procedure for the definite diagnosis of vasculitis. We elucidated the immunopathological features of skeletal muscle in VM by comparing the immunohistochemical (IHC) findings of skeletal muscle in patients with idiopathic inflammatory myositis (IIM).

Methods: The biopsied skeletal muscle tissues from 15 patients with VM, including antineutrophil cytoplasmic antibody-associated vasculitis and polyarteritis nodosa, and 15 with IIM, including polymyositis and immune-mediated necrotizing myopathy, were used in this study. IHC staining of skeletal muscle was performed as follows: CD56/neural cell adhesion molecule (NCAM) which detects myofiber damage and regeneration, major histocompatibility complex (MHC)-class I, C5b-9/membrane attack complex (MAC), and CD31 which is an endothelial cell marker. The vascularity score was defined as the total number of CD31-expressing blood vessels.

The counts and calculations of IHC stained samples and the vascularity scores were performed in the 10 different high-power fields.

Results: The frequency of NCAM-expressing myofibers was significantly lower in patients with VM than in those with IIM (p < 0.01) (Fig. 1). In addition, the frequency of NCAM-expressing myofibers was positively correlated with serum aldolase levels (p < 0.01). The frequency of MHC class I-expressing myofibers was significantly lower in patients with VM than in those with IIM (p < 0.005). A lower number of patients with MV had MAC-expressing myofibers on sarcolemma without intracellular staining than those with IIM (33% vs. 80%, p < 0.05).Meanwhile, the frequency of patients, who had MAC-expressing capillaries in endomysium areas, was not significantly different between VM and IIM (73% vs. 93%). Significantly higher vascularity scores in the endomysium areas were demonstrated in patients with MV than in those with IIM (p < 0.0005) (Fig. 2).

Conclusion: Mild myofiber damage, based on the result of less involving NCAM-expressing myofiber, was demonstrated in patients with VM than in those with IIM. Our results suggest that complement component deposits on vessel walls and hypervascularity in the endomysium areas may be immunopathological features of VM.

Supporting image 1

Fig.1: The frequencies of CD56/NCAM-expressing myofibers in the total myofibers between patients with vasculitic myopathy (VM) and those with idiopathic inflammatory myopathy (IIM).

Supporting image 2

Fig.2: The vascularity scores in the endomysium areas between patients with vasculitic myopathy (VM) and those with idiopathic inflammatory myopathy (IIM).


Disclosures: S. Nomura: None; Y. Shimojima: None; T. Ichikawa: None; D. Miyazaki: None; D. Kishida: None; Y. Sekijima: None.

To cite this abstract in AMA style:

Nomura S, Shimojima Y, Ichikawa T, Miyazaki D, Kishida D, Sekijima Y. Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/myopathy-related-to-small-to-medium-sized-vessel-vasculitis-immunopathological-characteristics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/myopathy-related-to-small-to-medium-sized-vessel-vasculitis-immunopathological-characteristics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology